Specifically, we selected propranolol (non-selective β-blocker) that is prescribed to treat CPVT [24, 25], verapamil (a dihydropyridine receptor inhibitor [DPHR]) that has been proposed to be a first-line treatment of short-coupled torsades de pointes [9], flecainide (Na+ channel inhibitor) known to be effective in treatment of CPVT [11] and S107 (stabilizer of the RyR2 closed state conformation) [21, 26]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.